KRAS and colorectal carcinoma: Despite promising preclinical evidence, recent trials in metastatic CRC patients with wild-type KRAS have shown no benefit from the combination of anti-EGFR and anti-IGF1-R-directed therapies as compared with EGFR-targeted monotherapy (45, 63).